Evidence map›Paper›PMID 39761813›Full record

ArticleBiomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals2025

Mutational and co-mutational landscape of early onset colorectal cancer.

Jumanah Yousef Alshenaifi, Guglielmo Vetere, Giulia Maddalena, Mahmoud Yousef, Michael G White, John Paul Shen, Eduardo Vilar, Christine Parseghian, Arvind Dasari, Van Karlyle Morris and 9 more

Abstract read
In one paragraph

Article in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Study on predicting microsatellite instability in rectal cancer using TCancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  9. Article
  10. Real-World Molecular Testing in European Early-Onset Colorectal Cancer.United European gastroenterology journal · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jumanah Yousef AlshenaifiDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4166-9830
Guglielmo VetereDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Giulia MaddalenaDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mahmoud YousefDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael G WhiteDepartment of Colon & Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John Paul ShenDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Eduardo VilarDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christine ParseghianDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Arvind DasariDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Van Karlyle MorrisDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ryan HueyDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael J OvermanDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert WolffDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kanwal P RaghavDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason WillisDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kristin AlfaroDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andy FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y Nancy YouDepartment of Colon & Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Scott KopetzDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

TRANSLATIONAL AND ANALYTICAL CHEMISTRY COREP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PETER W PISTERS · 1985 to 2026
$279.3M
Therapeutic Strategies for Patients With BRAF Mutant Colorectal CancerR01CA187238 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HONG, DAVID S., KOPETZ, SCOTT · 2014 to 2018
$1.7M
Stress Signaling Pathways and Resistance in Colorectal CancerR01CA172670 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT · 2013 to 2017
$1.6M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA172670NCI NIH HHS R01 CA187238
6 · The paper itself

Abstract

introductionColorectal cancer (CRC) incidence and mortality before 50 have been rising alarmingly in the recent decades.

methodsUsing a cohort of 10,000 patients, this study investigates the clinical, mutational, and co-mutational features of CRC in early-onset (EOCRC, < 50 years) compared to late-onset (LOCRC, ≥ 50 years).

resultsEOCRC was associated with a higher prevalence of Asian and Hispanic patients, rectal or left-sided tumors (72% vs. 59%), and advanced-stage disease. Molecular analyses revealed differences in mutation patterns, with EOCRC having higher frequencies of

conclusionThis study highlights the significance of age-specific molecular profiling, offering insights into the unique biology of EOCRC and potential clinical applications.

Indexed as

Colorectal NeoplasmsMutationAdultAgedAge of Onsetbeta CateninBiomarkers, TumorF-Box-WD Repeat-Containing Protein 7FemaleHumansMaleMicrosatellite InstabilityMiddle AgedProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Receptor, Notch1beta CateninBiomarkers, TumorBRAF protein, humanCTNNB1 protein, humanF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanKRAS protein, humanNOTCH1 protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Receptor, Notch1Smad4 ProteinSMAD4 protein, humanTP53 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein LigasesAPCEarly-onset colorectal cancerlate-onset colorectal cancernext-generation sequencingNGSTP53

Identifiers

PMID39761813
PMCPMC11856746

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.